Wikidata entity: Q423364
C₁₆H₂₁NO₂ (P274)
Quantities
| P2067 | mass | 259.157229 |
| P3780 | active ingredient in | ... | Q47521709 (Inderal) | Inderal |
| P3780 | active ingredient in | ... | Q48825946 (InnoPran) | InnoPran |
| P3780 | active ingredient in | ... | Q48826239 (Hemangeol) | Hemangeol |
| P233 | canonical SMILES | String | CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O | ??? |
| P373 | Commons category | String | Propranolol | ??? |
| P1889 | different from | ... | Q14985 (propyl alcohol) | propyl alcohol |
| P1889 | different from | ... | Q3407542 (propanol) | propanol |
| P703 | found in taxon | ... | Q948827 (Asimina triloba) | Asimina triloba |
| P1552 | has characteristic | ... | Q1517187 (bitterness) | bitterness |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P31 | instance of | ... | Q59199015 (group of stereoisomers) | group of stereoisomers |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P8026 | LiverTox likelihood score | ... | Q83284667 (LiverTox toxicity likelihood category E) | LiverTox toxicity likelihood category E |
| P2175 | medical condition treated | ... | Q12152 (myocardial infarction) | myocardial infarction |
| P2175 | medical condition treated | ... | Q124604 (portal hypertension) | portal hypertension |
| P2175 | medical condition treated | ... | Q133823 (migraine) | migraine |
| P2175 | medical condition treated | ... | Q180762 (angina pectoris) | angina pectoris |
| P2175 | medical condition treated | ... | Q154430 (anxiety) | anxiety |
| P2175 | medical condition treated | ... | Q41861 (arterial hypertension) | arterial hypertension |
| P2175 | medical condition treated | ... | Q2072821 (capillary hemangioma) | capillary hemangioma |
| P2175 | medical condition treated | ... | Q3377927 (PHACE association) | PHACE association |
| P2175 | medical condition treated | ... | Q536269 (phaeochromocytoma) | phaeochromocytoma |
| P2175 | medical condition treated | ... | Q544006 (anxiety disorder) | anxiety disorder |
| P2175 | medical condition treated | ... | Q693519 (essential tremor) | essential tremor |
| P2175 | medical condition treated | ... | Q741713 (panic disorder) | panic disorder |
| P2175 | medical condition treated | ... | Q19000661 (congestive heart failure) | congestive heart failure |
| P2175 | medical condition treated | ... | Q4458080 (thyroid crisis) | thyroid crisis |
| P2175 | medical condition treated | ... | Q848662 (ventricular fibrillation) | ventricular fibrillation |
| P2175 | medical condition treated | ... | Q1598909 (supraventricular tachycardia) | supraventricular tachycardia |
| P129 | physically interacts with | ... | Q287961 (adrenoceptor beta 2) | adrenoceptor beta 2 |
| P129 | physically interacts with | ... | Q21498865 (Adrenergic receptor, beta 3) | Adrenergic receptor, beta 3 |
| P129 | physically interacts with | ... | Q4897175 (adrenoceptor beta 3) | adrenoceptor beta 3 |
| P3489 | pregnancy category | ... | Q28123617 (US pregnancy category C) | US pregnancy category C |
| P3489 | pregnancy category | ... | Q3679261 (Australian pregnancy category C) | Australian pregnancy category C |
| P636 | route of administration | ... | Q285166 (oral administration) | oral administration |
| P636 | route of administration | ... | Q29913953 (intravenous administration) | intravenous administration |
| P1909 | side effect | ... | Q9690 (fatigue) | fatigue |
| P1909 | side effect | ... | Q217111 (bradycardia) | bradycardia |
| P1909 | side effect | ... | Q35869 (asthma) | asthma |
| P1909 | side effect | ... | Q177190 (sleep disorder) | sleep disorder |
| P1909 | side effect | ... | Q22909666 (Vivid dream) | Vivid dream |
| P769 | significant drug interaction | ... | Q58713 (clomipramine) | clomipramine |
| P769 | significant drug interaction | ... | Q58376 (fluphenazine) | fluphenazine |
| P769 | significant drug interaction | ... | Q58396 (imipramine) | imipramine |
| P769 | significant drug interaction | ... | Q58397 (amitriptyline) | amitriptyline |
| P769 | significant drug interaction | ... | Q409236 (fluvoxamine) | fluvoxamine |
| P769 | significant drug interaction | ... | Q410061 (amiodarone) | amiodarone |
| P769 | significant drug interaction | ... | Q410291 (verapamil) | verapamil |
| P769 | significant drug interaction | ... | Q410492 (lercanidipine) | lercanidipine |
| P769 | significant drug interaction | ... | Q411887 (rivastigmine) | rivastigmine |
| P769 | significant drug interaction | ... | Q412221 (clonidine) | clonidine |
| P769 | significant drug interaction | ... | Q251347 (haloperidol) | haloperidol |
| P769 | significant drug interaction | ... | Q423498 (trimipramine) | trimipramine |
| P769 | significant drug interaction | ... | Q425120 (disopyramide) | disopyramide |
| P769 | significant drug interaction | ... | Q425137 (fingolimod) | fingolimod |
| P769 | significant drug interaction | ... | Q425296 (prazosin) | prazosin |
| P769 | significant drug interaction | ... | Q412621 (methyldopa) | methyldopa |
| P769 | significant drug interaction | ... | Q413188 (methacholine) | methacholine |
| P769 | significant drug interaction | ... | Q418480 (tamsulosin) | tamsulosin |
| P769 | significant drug interaction | ... | Q280786 (terazosin) | terazosin |
| P769 | significant drug interaction | ... | Q419186 (ergotamine) | ergotamine |
| P769 | significant drug interaction | ... | Q419939 (doxazosin) | doxazosin |
| P769 | significant drug interaction | ... | Q419944 (moxonidine) | moxonidine |
| P769 | significant drug interaction | ... | Q2736873 (alfuzosin) | alfuzosin |
| P769 | significant drug interaction | ... | Q422222 (digoxin) | digoxin |
| P769 | significant drug interaction | ... | Q422229 (diltiazem) | diltiazem |
| P769 | significant drug interaction | ... | Q662511 ((RS)-propafenone) | (RS)-propafenone |
| P769 | significant drug interaction | ... | Q407972 (chlorpromazine) | chlorpromazine |
| P769 | significant drug interaction | ... | Q408637 (dronedarone) | dronedarone |
| P769 | significant drug interaction | ... | Q736270 (mefloquine) | mefloquine |
| P769 | significant drug interaction | ... | Q5186964 (crizotinib) | crizotinib |
| P769 | significant drug interaction | ... | Q5459971 (floctafenine) | floctafenine |
| P769 | significant drug interaction | ... | Q4973749 (bromperidol) | bromperidol |
| P769 | significant drug interaction | ... | Q47495783 ((−)-selegiline) | (−)-selegiline |
| P769 | significant drug interaction | ... | Q50316261 (adrenergic beta-agonists) | adrenergic beta-agonists |
| P769 | significant drug interaction | ... | Q71704041 ((E/Z)-doxepin) | (E/Z)-doxepin |
| P279 | subclass of | ... | Q2832211 (secondary alcohol) | secondary alcohol |
| P279 | subclass of | ... | Q43305851 (phenol ether) | phenol ether |
| P279 | subclass of | ... | Q73304699 (secondary amine) | secondary amine |
| P2868 | subject has role | ... | Q35456 (essential medicine) | essential medicine |
| P2868 | subject has role | ... | Q241549 (antiarrhythmic agent) | antiarrhythmic agent |
| P2868 | subject has role | ... | Q575890 (antihypertensive drug) | antihypertensive drug |
| P2868 | subject has role | ... | Q4008956 (vasodilator agent) | vasodilator agent |
| P2868 | subject has role | ... | Q816759 (beta blocker) | beta blocker |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | propranolol | ??? |
Why not click here or view trends?
log id: 2554327